Please login to the form below

Not currently logged in

Prix Galien shortlist announced

Janssen-Cilag picks up three nominations in awards to recognise advances in pharma research

Janssen-Cilag has three drugs among the shortlist for this year's coveted UK Prix Galien medals, recognising significant advances in pharmaceutical research.

In total of 12 medicines, from ten pharma companies, will battle it out in the 2012 awards, with the winners announced during a ceremony at the UK's House of Commons this September.

Janssen-Cilag's nominations in the Innovative Product category are Xeplion (paliperidone palmitate) for schizophrenia, prostate cancer drug Zytiga (abiraterone acetate) and Incivo (telaprevir).

The other eight products in this category are: Amgen's Xgeva (denosumab) for bone complications of cancer; AstraZeneca's Brilique (ticagrelor) for acute coronary syndromes; Bayer's anticoagulant Xarelto (rivaroxaban); Bristol Myers Squibb's melanoma treatment Yervoy (ipilimumab); Novartis' oral multiple sclerosis treatment Gilenya (fingolimod); Roche's Zelboraf (vemurafenib) for melanoma; Shire's Resolor (prucalopride) for chronic constipation in women; and MSD's hepatitis C treatment Victrelis (boceprevir).

The Orphan Drug Award has just one candidate, namely Takeda UK's Mepact (mifamurtide) for osteosarcoma.

All shortlisted products were launched or granted a new indication in the UK between 1 January 2010 and 31 March 2012.

The 2012 UK Prix Galien awards comes at a time when the value of medical innovation finds itself under great scrutiny in the UK, according to the organisers, who point to the findings of the Innovation Health and Wealth Review last year, which highlighted the "growing need to accelerate the adoption and diffusion of innovation in the NHS".

NICE Chairman Professor Sir Michael Rawlins, who is leading the judging panel for the prizes, said: "the challenge for the UK pharmaceutical industry is to demonstrate that its medicines truly add value, and can help the NHS meet its quality and productivity goals."

The 2012 ceremony will take place on September 26, 2012, with former shadow health minister Kevin Barron taking over from Lord Walton of Detchant as the Parliamentary sponsor.

The UK Prix Galien awards take place every two years. In 2010, the two medals were awarded to Bayer's Xarelto and Shire's Firazyr (icatibant), a treatment for the rare hereditary condition angioedema.

30th May 2012


Featured jobs

Subscribe to our email news alerts


Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....